GSK Acquires Efimosfermin Alfa from Boston Pharmaceuticals in $2 Billion Deal for Liver Disease Treatment
GSK has agreed to acquire efimosfermin alfa, a phase III-ready liver disease drug, from Boston Pharmaceuticals in a deal worth up to $2 billion.
GSK Acquires Efimosfermin for $1.2 Billion to Target Steatotic Liver Disease
GSK has agreed to acquire efimosfermin alfa from Boston Pharmaceuticals for $1.2 billion upfront, with potential additional milestone payments of $800 million, strengthening its hepatology pipeline.
Efimosfermin Alfa Shows Promise in Phase II MASH Trial with Monthly Dosing
Boston Pharmaceuticals' efimosfermin alfa demonstrated statistically significant fibrosis improvement in MASH patients, with 45.2% showing at least a one-stage improvement compared to 20.6% in the placebo group.
Efimosfermin Alfa Shows Promise in Phase 2 MASH Trial
Efimosfermin alfa demonstrated statistically significant improvement in liver fibrosis without worsening of MASH compared to placebo over 24 weeks.
GSK Acquires Boston Pharmaceuticals' Efimosfermin for Liver Disease in $2 Billion Deal
GSK has agreed to acquire Boston Pharmaceuticals' phase 3-ready liver disease candidate efimosfermin alfa for $1.2 billion upfront, with potential milestone payments bringing the total to $2 billion.